ESTA,Establishment Labs Holdings Inc. | Healthcare

Healthcare

ESTA

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Establishment Labs Holdings Inc.ESTA

USD

+2.68 (7.89%)

Jun 3, 2025, 4:00 PM - At close

USD

+0.25 (0.68%)

Jun 3, 2025, 7:33 PM EDT - Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

1.06B

Revenue (ttm)

170.24M

Net Income (ttm)

-89.10M

Shares Out

28.92M

EPS (ttm)

-3.12

PE Ratio

n/a

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

302,306

Open

34.92

Previous Close

33.97

Day's Range

34.84 - 36.65

52-Week Range

26.56 - 58.00

Beta

0.73

Analysts

Strong Buy

Price Target

57.57 (+57.08%)

Earnings Date

May 7, 2025

Description >

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery.

The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

The company sells its products through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia.

Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Latest News >

JPMorgan's Net Interest Income Outlook Is 'Moderate Disappointment' Amid 'Solid' Q1 Results, HSBC Says

Apr 12, 2024

12:02 PM EDT, 04/12/2024 (MT Newswires) -- JPMorgan Chase's ( JPM ) net interest income outlook this year probably was assessed as a moderate disappointment amid solid Q1 results on a decrease in loan losses, higher non-interest income and lower expenses, HSBC Global Research said Friday in a note. JPMorgan ( JPM ) kept its 2024 net interest income outlook...

Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

Apr 12, 2024

Friday, PaxMedica Inc ( PXMD ) completed the execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an essential milestone in enabling a New Drug Application submission to the FDA, which is currently planned for Q4 2024, and the potential commercial availability in the U.S. of the first and only form of suramin for Stage...

Update: Corus Entertainment Falls 20% as it Meets Fiscal Q2 Forecasts But Sees Drop in FQ3 TV Advertising Revenues

Apr 12, 2024

12:00 PM EDT, 04/12/2024 (MT Newswires) -- Corus Entertainment (CJR-B.TO) on Friday said its fiscal second-quarter loss narrowed while it warned it expects lower advertising revenue for its current quarter. The broadcaster reported a fiscal second-quarter adjusted loss of C$5.94 million, or C$0.03 per share, in the quarter ended Feb.29, narrowing from a loss of C$13.88 million, or C$0.07 per...

European Equities Close Mixed in Friday Trading; German Inflation Slows, UK GDP Rises

Apr 12, 2024

12:08 PM EDT, 04/12/2024 (MT Newswires) -- European stock markets closed mixed in Friday trading as the Stoxx Europe 600 was up 0.14%, the Swiss Market Index lost 0.75%, France's CAC was off 0.16%, the FTSE in London rose 0.91%, and Germany's DAX was down 0.13%. In Germany, the consumer price index was 2.2% in March, down from 2.5% in...